Balancing Safety and Efficacy: Optimizing Topical Treatment Options for AD

Casey Butrus, PharmD; Michael Cameron, MD, FAAD, and Brittany Craiglow, MD, provide insights on the differences between therapies that require continuous use versus those that can be intermittently used for atopic dermatitis (AD), explore the potential of combination therapy, and discuss optimal efficacy and duration of therapy regimens to maximize patient outcomes.

  1. When it comes to topical ruxolitinib, how do you balance the efficacy versus the safety when deciding to treat patients with it?
  2. How do treatment options differ in terms of administration schedule (continuous versus non-continuous), and how does the need for breakthrough topical steroids influence your decision on therapy options?
  3. In the managed care space, what is the role of combination therapy in AD and what restrictions might be considered?
  4. From a payer’s perspective, how do you take into account when a product does not need continuous use and still be efficacious, potentially allowing for time off therapy?
Related Videos
1 KOL is featured in this series.
1 KOL is featured in this series.
timothy caulfield, JD
dr ibrahim aldoss
dr anna sureda
Related Content
CH LogoCenter for Biosimilars Logo